EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors

Mai Abdel Mouti, Siim Pauklin

Trends in Pharmacological Sciences · 2023-05 · 44 (5) · 255-257

DOI: 10.1016/j.tips.2023.02.004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Pharmacological Sciences, 2023-05. Verfasst von Mai Abdel Mouti und 1 weiteren Autor:innen. Beteiligte Einrichtung: Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The clinical efficacy and durability of KRASG12C-targeted therapies are limited by the development of resistance mechanisms. Here, we provide a review of recent KRASG12C-targeted therapy and immunotherapy-unifying strategies that utilize covalently modified peptide/MHC class I complexes as tumor-specific neoantigens to tag drug-resistant cancer cells for destruction with hapten-based immunotherapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)NeoplasmsHumansMutationTreatment OutcomeImmunotherapy

Stichwörter der Autor:innen

KRAS(G12C)immunotherapyneoantigensresistancetargeted therapy

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, human

Autor:innen und Institutionen

  • Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK.
  • Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7LD, UK. Electronic address: siim.pauklin@ndorms.ox.ac.uk.

Förderung

  • Cancer Research UK

Zitieren

APA

Abdel Mouti, M., & Pauklin, S. (2023). Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors. Trends in Pharmacological Sciences, 44(5), 255-257. https://doi.org/10.1016/j.tips.2023.02.004

Vancouver

Abdel Mouti M, Pauklin S. Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors. Trends in Pharmacological Sciences. 2023;44(5):255-257. doi:10.1016/j.tips.2023.02.004

BibTeX
@article{AbdelMouti2023,
  author = {Abdel Mouti, Mai and Pauklin, Siim},
  title = {Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors},
  journal = {Trends in Pharmacological Sciences},
  year = {2023},
  volume = {44},
  number = {5},
  pages = {255--257},
  doi = {10.1016/j.tips.2023.02.004}
}
Kostenlos starten →